Furthermore, EBV+ DLBCL presents with a distinct tolerogenic TME than EBV− DLBCL, characterized by elevated expression of immune checkpoints [PD‐L1, PD‐L2, lymphocyte activation gene 3 (LAG-3) and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)] and high levels of immunosuppressive M2‐type macrophages (12). This evidence concerns the gene LAG3 and diffuse large B-cell lymphoma.